AAN 2021 | The complexities of Parkinson’s disease subtyping
Alberto Espay, MD, FAAN, University of Cincinnati, Cincinnati, OH, discusses the downfalls of current attitudes towards subtyping in Parkinson’s disease (PD). PD is a complex disease with heterogeneous clinical subtypes. Thus, the development of reliable biomarkers is critical for improved clinical management. However, many investigational biomarkers have shown significant patient variability and low reproducibility over time. New ways of approaching the identification of biological markers in PD are needed. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.
Disclosures
Dr. Espay has received grant support from the NIH and the Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Abbvie, Neuroderm, Neurocrine, Amneal, Acadia, Acorda, Kyowa Kirin, Sunovion, Lundbeck, and USWorldMeds; honoraria from Acadia, Sunovion, Amneal, USWorldMeds; and publishing royalties from Lippincott Williams & Wilkins, Cambridge University Press, and Springer. He cofounded REGAIN Therapeutics, owner of a patent application that covers synthetic soluble non-aggregating peptide analogues as replacement treatment in proteinopathies. He serves on the editorial boards of the Journal of Parkinson’s Disease, European Journal of Neurology, and JAMA Neurology.
